GlassScriptPhysician profile
Christopher Michael Rivard
NPI 1396204525
$2,341.10
in general payments reported to CMS, 2019-2025
16 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.25 · 2023: $466 · 2024: $1,222 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.85 | 2023-2025 | Skyrizi |
| Lilly USA, LLC | $521.01 | 2022-2025 | Zepbound, Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $216.04 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $182.34 | 2023-2025 | |
| Ucb, INC. | $126.75 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2023 | Sotyktu |
| Pfizer INC. | $121.36 | 2024 | |
| Arcutis Biotherapeutics, INC. | $77.61 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $57.38 | 2022-2025 | Tremfya |
| Smith+Nephew, INC. | $52.30 | 2024 | Grafix Pl |
| Incyte Corporation | $50.41 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $44.27 | 2024-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $37.18 | 2023-2025 | Ilumya |
| Galderma Laboratories, L.P. | $33.23 | 2025 | Nemluvio |
| Organon LLC | $20.19 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $19.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rivard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.